Influence of Hormone Therapy and Testosterone Level on All Cause Survival after Brachytherapy for Localized Prostate Cancer

Nelson N. Stone MD and Richard G. Stock MD
Departments of Urology and Radiation Oncology, The Icahn School of Medicine at Mount Sinai, New York, NY

Materials/Methods

• 1776 men with a median age of 66 years (range 31-84) were followed a minimum of 6 years (mean 10.3, range 6-22.4) and had PSI alone or with neoadjuvant hormone therapy (NHT) and or external beam irradiation boost (EBRT).
• NHT was given to 948 (53.4%) for a median of 6 months (75th percentile 3-9). T level was available in 1140 (64.2%) a median of 6.3 years (75th percentile 3.2-9.2) following treatment.
• Information on co-existing medical conditions including diabetes (AODM), coronary artery disease, alcohol use, asthma, atrial fib, other cancers, heart disease, hypertension, stroke and emphysema was determined pre-treatment.

CONCLUSIONS

• NHT > 6 months is associated with lower testosterone
• Lower testosterone is associated with lower ACS
• NHT should be limited to 6 months in men treated with brachytherapy